Last reviewed · How we verify
Amaryl®
At a glance
| Generic name | Amaryl® |
|---|---|
| Sponsor | PT Harsen Laboratories |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (PHASE4)
- Glimepiride 4 mg Tablets Under Non-Fasting Conditions (PHASE1)
- Glimepiride 4 mg Tablets Under Fasting Conditions (PHASE1)
- Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg (PHASE1)
- Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg (PHASE1)
- Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects (NA)
- Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass (NA)
- COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amaryl® CI brief — competitive landscape report
- Amaryl® updates RSS · CI watch RSS
- PT Harsen Laboratories portfolio CI